Backgrounders
Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
August 30, 2018
The I-SPY 2 TRIAL is an innovative research study for women with newly diagnosed locally advanced breast cancer. The aim is to test new investigational drugs with or without standard chemotherapy in the search for improving outcomes.
The I-SPY 2 researchers will test a variety of drugs with the goal of trying to personalize treatment for breast cancer patients in the future.
The I-SPY 2 TRIAL = Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis 2.
The goal of I-SPY 2 is to help us learn if adding investigational drugs with standard chemotherapy will improve the treatment of breast cancer. Having chemotherapy prior to surgery, or neoadjuvant chemotherapy, allows you and the researchers to see how your tumor responds to treatment.
In I-SPY 2, you will be assigned treatment with or without investigational drugs based on your tumor characteristics. The structure of this trial allows us to learn more quickly which investigational drugs will be most beneficial for women with your particular tumor biology.
You will be closely monitored to see how your tumors respond to your treatment. MRIs, core biopsies, and blood draws will also help identify tumor characteristics that will help researchers learn how individual tumors respond to new drugs.
Kristen Zeitzer
Quantum Leap Healthcare Collaborative
(855) 866-0505 x115
k.zeitzer@quantumleaphealth.org
Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.
